WebOct 17, 2024 · Founded in 2016, Breath Therapeutics is a biopharmaceutical company specializing in advanced inhaled therapeutics for severe respiratory diseases with high unmet medical need. The company's proprietary drug formulations have been specifically designed for inhaled administration with exclusively licensed, high performance nebulizer … WebJul 29, 2024 · Breath Therapeutics (BREATH), based in Munich, Germany and Menlo Park, California, US, is a biopharmaceutical company specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases with high unmet medical need. BREATH’s drug candidate is L‑CsA‑i, a novel proprietary liposomal formulation of …

Breath Therapeutics Holding BV Spins Out of PARI Pharma With …

WebIn 2024, Breath Therapeutics secured financing from a European investor syndicate, including Sofinnova Partners, Gimv and Gilde Healthcare. The proceedings have been used to initiate the drug candidate’s Phase III studies, commercial-scale production of the drug and related device, and for commercial activities towards future launch. WebOct 16, 2024 · Milan, Italy, Munich, Germany and Menlo Park, Calif. – October 17, 2024 – Breath Therapeutics, a Zambon company, a biopharmaceutical company specializing in advanced inhaled therapeutics for severe respiratory diseases with high unmet medical need, today announced presentations at three upcoming scientific conferences. property for sale radcliffe road bolton

Breath Therapeutics — Sofinnova Partners

WebJul 25, 2024 · Today, Gimv, Sofinnova and Gilde Healthcare announced the sale of biopharmaceutical company Breath Therapeutics. Specialising in advanced and first-in-class inhalation therapies for severe respiratory diseases, Breath Therapeutics collected around EUR 43.5 million in one of the largest start-up financing rounds in 2024. WebMar 26, 2024 · Breath Therapeutics . Founded in 2016, Breath Therapeutics is a private, venture-backed clinical stage biopharmaceutical company specializing in advanced … WebSep 5, 2024 · The objective of the trial is to assess efficacy and safety of add-on aerosolized liposomal cyclosporine A (L-CsA) to Standard of Care (SoC) therapy as compared to SoC therapy alone in the treatment of Bronchiolitis obliterans syndrome (BOS) in single lung transplant recipients. Detailed Description: property for sale rampton notts